Company Profile
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company provides the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and globally.
Its business is organized into five segments: Gene-Editing. Its portfolio also includes Pharmacological Efficacy, Model Animals, Antibody Development, and Other. The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers.
Its portfolio also includes provides the pre-clinical pharmacology service for drug efficacy and toxicity evaluation, engages in breeding and selling animal models for the external and internal use
Including set of genetically engineered mice, disease mouse models and aged small animals, engages un utilizing the Group's own antibody discovery platforms to identify antibodies which have the potential to become drug candidates, and engages in R&D of innovative drugs with a focus on oncology and autoimmune disease therapeutics
YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody for the treatment of patients with advanced solid tumors
It also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial.
The company has collaboration with Syncromune, Inc. Its portfolio also includes a license agreement with RemeGen Co., Ltd., and license agreement with Chipscreen NewWay Biosciences. Founded in 2008, Biocytogen Pharmaceuticals (Beijing) is headquartered in Beijing, China.